Update (June 16, 2026): Proof-of-Concept DNA-Plasmid Vaccine Improves Pruritus and Lesion Scores in Dogs With Atopic Dermatitis

TL;DR. A proof-of-concept study reports that an intradermal DNA-plasmid vaccine targeting house-dust-mite allergen improved pruritus and lesion scores in dogs with atopic dermatitis, hinting at a future allergen-specific option alongside today's cytokine-targeted drugs.

What just dropped

• Proof-of-concept clinical study in 35 client-owned dogs with nonseasonal atopic dermatitis sensitised to Dermatophagoides farinae (https://europepmc.org/articles/PMC12967877): a Der f 2/Zen 1-LAMP plasmid DNA vaccine, given as four intradermal doses across an eight-week course, improved pruritus and CADESI-04 lesion scores regardless of sensitisation profile or vaccine dose.
• After 24 weeks, 71%, 46% and 86% of dogs reached pruritus VAS below 3.6, below 2, and CADESI-04 below 10, respectively; 60% of owners rated efficacy good-to-excellent and no severe adverse events were reported.
• A 2025 review of anti-cytokine drugs (https://europepmc.org/articles/PMC12652870) frames the current landscape, describing lokivetmab's IL-31 neutralisation, the JAK inhibitors oclacitinib and ilunocitinib, and ciclosporin as a long-term immunosuppressant.

Context

Canine atopic dermatitis management has shifted toward targeted, mechanism-based therapies. The Wichtowska 2025 review describes this as a paradigm shift from non-specific immunosuppression toward precision medicine: lokivetmab neutralises interleukin-31, JAK inhibitors block downstream cytokine signalling, and ciclosporin remains a valuable long-term option. These control inflammation and itch but do not retrain the underlying allergic response.

Allergen-specific immunotherapy aims at that underlying response. The Bizikova 2026 study tested a DNA-plasmid vaccine encoding a house-dust-mite allergen fused to a lysosomal-targeting protein to boost immune responses. Fifteen dogs reactive to Dermatophagoides farinae only and 20 with additional environmental allergens received the vaccine; pruritus and lesion scores improved over 24 weeks, and the authors noted concurrent topical or systemic treatments were unlikely to explain the improvement. They emphasise this is a proof-of-concept result requiring a larger, longer, double-blinded controlled study to confirm true efficacy.

What this changes in oclacitinib (Apoquel) for canine atopic dermatitis (https://www.thevoyage.ai/forvets/knowledge/oclacitinib-canine-atopic-dermatitis)

Nothing changes in current practice or dosing, which remains a label and formulary matter. But this is an early signal that allergen-specific DNA-vaccine immunotherapy could eventually complement the cytokine-targeted drugs that anchor the dermatology evergreens. It is worth tracking as the controlled follow-up study the authors call for is completed.

Voyage Clinical Desk

From clinical question to SOAP draft -- cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-16-canine-ad-dna-vaccine-immunotherapy

References

1. Bizikova P, Matsumoto C, Ogino S, et al. Efficacy of Der f 2/Zen 1-LAMP1 Plasmid-Based Vaccine Immunotherapy in Dogs With Atopic Dermatitis: A Proof-of-Concept Study. Vet Dermatol. 2026;37(2):306-318. https://europepmc.org/articles/PMC12967877
2. Wichtowska A, Olejnik M. Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis. Int J Mol Sci. 2025;26(22):10990. https://europepmc.org/articles/PMC12652870

Related reads

• Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
• Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence